ASH 2023 | Updated results of the AAA regimen in newly-diagnosed acute promyelocytic leukemia
Harinder Gill, MBBS, PDipID, MD, MRCP, FRCPath, FHKCP, FHKAM, The University of Hong Kong, Hong Kong, China, discusses updated results of an ongoing multicenter trial of the combination of oral-arsenic trioxide, all-trans retinoic acid, and ascorbic acid (the AAA regimen), with minimized chemotherapy, in patients with newly-diagnosed acute promyelocytic leukemia (APL) (NCT04687176). The study aims to evaluate the efficacy, safety, and molecular responses of this therapeutic approach in these patients, and to date, the safety and efficacy data have been encouraging. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: BMS, Pfizer, GSK, Novartis, PharmaEssentia
Conference support: Pfizer, Novartis, PharmaEssentia
Research Funding: Imago BioSciences, Inc. (a subsidiary of Merck & Co., Inc.), Novartis, PharmaEssentia
